Using metformin to treat melasma in Latin American women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of metformin in reducing melasma in Latin American women. Participants will take either 500 mg or 1000 mg of metformin daily for three months. The study involves two clinic visits, one at the start and one at the end, along with follow-up phone calls to monitor progress and side effects. The primary focus is to determine if metformin can improve the appearance of dark patches associated with melasma.

Why it matters

Who can join: the full rules

Inclusion Criteria: Latin American women aged 21 years or older, diagnosed epidermal or mixed melasma

Exclusion Criteria: pregnancy, breastfeeding, use of hydroquinone or tretinoin within 2 months before the study, or undergoing laser treatment, peels, microdermabrasion, or microneedling within 2 months of the study. Patients with a history of renal or liver disease, metformin allergy, diabetes, hypoglycemia, or those on medications that could interact with metformin will also be excluded.

Where it's running

• Administración de Servicios Médicos (ASEM) Clinicas Externas
  San Juan, Pr, Puerto Rico Recruiting

Study contacts

• Principal investigator: Cristina Brau — University of Puerto Rico
• Study coordinator: Cristina Brau
• Email: cbrau@skinbybrau.com
• Phone: 787-758-2525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Face sunscreen with untinted or tinted formula to improve dark spots after 8 weeks

  This study tests whether using a facial sunscreen (untinted or tinted) for 8 weeks can improve facial dark spots in adults with conditions like melasma, solar lentigines, or post-inflammatory hyperpigmentation.

  Recruiting Kenvue Brands LLC · Campinas, São Paulo · NCT07679945

• Injectable platelet-rich fibrin versus intradermal tranexamic acid for facial melasma

  This compares injections of a patient's own platelet-rich fibrin with tiny intradermal tranexamic acid shots to see which reduces facial melasma better in adult women.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07540702

• Using SM-030 Gel to Treat Melasma in Adults

  This study is testing two different strengths of a new gel to see if it can help adults with melasma improve their skin, compared to a placebo gel.

  Recruiting at 2 sites Phase 2 DermBiont, Inc. · Santa Tecla, La Libertad Department and 1 other locations · NCT06454747

• Cosmetic gel for facial hyperpigmentation in women

  This study tests a depigmenting gel to see if it improves facial dark spots in 40 women aged 30–60 over 90 days.

  Recruiting Brainfarma Industria Química e Farmacêutica S/A · Osasco, São Paulo · NCT07769268

• Ultrasound-enhanced delivery of tranexamic acid and glutathione for facial melasma

  This trial will test whether using ultrasound to help the skin absorb a 10% tranexamic acid and 2% glutathione solution reduces facial melasma in adults aged 20–55.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07202156

• Cosmetic serum versus 4% hydroquinone for treating facial melasma over 84 days

  This trial tests whether a cosmetic depigmenting serum lightens mild-to-moderate facial melasma and is gentler on the skin than a 4% hydroquinone cream in adults 18–65.

  Recruiting Laboratoire Dermatologique ACM · Port Louis, Phoenix · NCT07071363

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.